Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody: delandistrogene moxeparvovec, suvodirsen sodium, suvodirsen +5 | 0.45 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 36 Parkinson's papers of 12,125 | 0.53 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3654
Sealed predictions
- DMD in dopamine neurons, braak+0.21 (p 0.591) → +0.30 (p 0.441)receipt 3661
Swarm cases
receipt 3661: DMD in dopamine neurons, braak
- power
- full sample +0.34 (p 0.173, n 18), 95% CI -0.16 to +0.69. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.62 (p 0.0062, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.60 (p 0.0089, n 18). not the mix.
- skeptic
- leave-one-out range +0.24 to +0.50, sign flips 0; without severely affected donors +0.34 (p 0.173, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for DMD in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts